Tribute Pharmaceuticals to Present at the Bloom Burton & Co. Annual Healthcare Conference
June 16 2014 - 7:00AM
Marketwired
Tribute Pharmaceuticals to Present at the Bloom Burton & Co.
Annual Healthcare Conference
LONDON, ONTARIO--(Marketwired - Jun 16, 2014) - Tribute
Pharmaceuticals Canada Inc. ("Tribute" or "the Company")
(TSX-VENTURE:TRX) (OTCQB:TBUFF), a specialty pharmaceutical company
with a primary focus on the acquisition, licensing, development and
promotion of healthcare products in Canada and the U.S., today
announced today that its President and Chief Executive Officer, Rob
Harris, will present an update on the Company and its corporate
activities, at the Bloom Burton & Co. ("Bloom Burton") Annual
Healthcare Investor Conference, to be held on Wednesday, June 18 at
the Toronto Board of Trade.
Bloom Burton's third
annual healthcare investor conference features Canada's premier
publicly-traded and venture-backed private companies. The event
will attract Canadian, U.S. an European investors who are
interested in the latest developments in Canadian healthcare
companies.
Tribute's corporate
presentation will be available on the Company's website at
http://www.tributepharma.com following the presentation.
About Tribute Pharmaceuticals Canada
Inc.
Tribute is a
specialty pharmaceutical company with a primary focus on the
acquisition, licensing, development and promotion of healthcare
products in Canada and the U.S. markets.
Tribute markets
Cambia® (diclofenac potassium for oral solution), Bezalip® SR
(bezafibrate), Soriatane® (acitretin), NeoVisc® (1.0% sodium
hyaluronate solution) Uracyst® (sodium chondroitin sulfate solution
2%) and Collatamp G® in the Canadian market. Additionally, NeoVisc®
and Uracyst® are commercially available and are sold globally
through various international partnerships. Tribute also has the
exclusive U.S. rights to develop and commercialize Bezalip® SR in
the U.S. and has the exclusive right to sell bilastine a product
licensed from Faes Farma for the treatment of Allergic Rhinitis and
Chronic Idiopathic Urticaria (hives) in Canada. The exclusive
license is inclusive of prescription and non- prescription rights
for bilastine, as well as adult and pediatric presentations in
Canada. This product is subject to receiving Canadian regulatory
approval.
Tribute Pharmaceuticals' Forward
Looking Statement
This press release
contains certain forward-looking statements about Tribute as
defined in the Private Securities Litigation Reform Act of 1995,
which statements can be identified by the use of forward- looking
terminology, such as "may", "will", "expect", "intend",
"anticipate", "estimate", "predict", "plan" or "continue" or the
negative thereof or other variations thereon or comparable
terminology referring to
future events or
results. Forward-looking statements, by their nature, are subject
to risks and uncertainties, Tribute actual results could differ
materially from those anticipated in these forward- looking
statements as a result of numerous factors, any of which could
cause actual results to vary materially from current results or
anticipated future results. See Tribute reports filed with the
Canadian Securities Regulatory Authorities and the U.S. Securities
and Exchange Commission from time to time for cautionary statements
identifying important factors with respect to such forward-looking
statements, including certain risks and uncertainties that could
cause actual results to differ materially from results referred to
in forward-looking statements. Tribute assumes no obligation to
update the information contained in this press release to update
forward-looking statements to reflect changed assumptions, the
occurrence of anticipated events or changes in future operating
results, financial condition or business over time.
Bezalip®SR and
Soriatane® are registered trademarks and under license from Actavis
Group PTC ehf. Cambia® is a registered trademark and under license
from Depomed, Inc. Collatamp G® is a registered trademark and under
license EUSA Pharma (Europe) Limited.
For further
information on Tribute visit the Company's website:
http://www.tributepharma.com
Neither TSX
Venture Exchange nor its Regulation Services Provider (as that term
is defined in policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this
release.
Tribute Pharmaceuticals Canada Inc.Scott
LangilleCFO905-876-3166scott.langille@tributepharma.comKevin
FicklePresident, Nuwa Group LLC(925)
330-8315Kevin@nuwagroup.com
Tribute Pharmaceuticals Canada (TSXV:TRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Tribute Pharmaceuticals Canada (TSXV:TRX)
Historical Stock Chart
From Jul 2023 to Jul 2024